contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


medicover-announces-new-financial-targets-continued-organic-growth-and-margin-expansion

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Medicover operates in the healthcare industry. The company is an international healthcare and diagnostics company and focuses on providing medical services and laboratory analyses. The company's services are aimed at individuals and companies that need fast and accessible care. Medicover was founded in 1994 and is headquartered in Stockholm, Sweden.

Medicover

The board of directors of Medicover AB (publ) (“Medicover”) has decided on new financial targets for the three-year period 2026-2028.The new financial targets[1] builds on the successful delivery...

<div class="mfn-preamble"><p><strong>The board of directors of Medicover AB (publ) (“Medicover”) has decided on new financial targets for the three-year period 2026-2028.</strong></p></div><div class="mfn-body"><p>The new financial targets[1] builds on the successful delivery during the 2023-2025 period and reflects the ambition to continuing to drive strong organic revenue growth and margin expansion, alongside financial discipline and continuous shareholder returns.</p><ul><li>Organic revenue exceeding EUR 3.25 billion in 2028</li><li>Organic adjusted EBITDA in excess of EUR 600 million in 2028</li><li>Loans payable net of cash and liquid short-term investments / adjusted EBITDAaL for the last twelve months ≤3.0x[2]</li><li>Dividend payout ratio up to 50 per cent of net profit for the year</li></ul><p><em>“Medicover is well positioned in markets with attractive fundamentals, demonstrated by our strong track record of profitable organic growth. Looking ahead, we will continue to expand our network and product offering, improve capacity utilisation, and capture synergies across countries and divisions. In parallel, we will accelerate technology initiatives to drive efficiency and further enhance quality of care. This underpins our confidence in delivering continued organic growth and margin expansion, alongside financial discipline,”</em> says John Stubbington, CEO of Medicover.</p><p>The company will hold an Investor Update on Wednesday 11 February at 13.00 CET. The webcast can be watched <a rel="noopener" href="https://medicover.events.inderes.com/investor-update-2026/register">here</a>.</p><p>Information on the Investor Update and live stream can be found on the <a rel="noopener" href="https://www.medicover.com/sv/capital-markets-day">website</a>.</p><p><strong>For further information, please contact:</strong><br>Hanna Bjellquist, Head of Investor Relations<br>+46 703 033 272<br><a rel="noopener" href="mailto:hanna.bjellquist@medicover.com">hanna.bjellquist@medicover.com</a></p><p><em>Medicover is a leading international healthcare and diagnostic services company and was founded in 1995. Medicover operates a large number of ambulatory clinics, hospitals, specialty-care facilities, laboratories and blood-drawing points and the largest markets are Poland, Germany, Romania and India. In 2024, Medicover had revenue of €2,092 million and more than 47,000 employees. For more information, go to </em><em><a rel="noopener" href="http://www.medicover.com/">www.medicover.com</a></em></p><p>[1] Under IFRS accounting standards as of year-end 2025.<br>[2] Can be exceeded over shorter periods.</p></div><div class="mfn-footer mfn-regulatory mfn-regulatory-mar"><p><em>This information is information that Medicover AB (Publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-02-09 18:51 CET.</em></p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong><br><a rel="noopener" href="https://storage.mfn.se/daa81f1b-0d4a-4446-85e5-7c8ad1deb452/medicover-announces-new-financial-targets-continued-organic-growth-and-margin-expansion.pdf" class="mfn-generated mfn-primary">Medicover announces new financial targets - continued organic growth and margin expansion</a></p></div>

Medicover announces new financial targets - continued organic growth and margin expansion